Mudasir Nabi Peerzada
Medicinal Chemistry Research laboratory, IndiaTitle: Design, Synthesis and Pharmacological Assessment of Novel Aryloxime-Morpholine Hybrids as Potential Microtubule Affinity-Regulating Kinase 4 Inhibitors and Anticancer Agents
Abstract:
Human African and American trypanosomiasis are the vector-borne parasitic diseases that have killed millions of people early, and many people are still suffering from these neglected diseases. The causative agents of these infections are parasitic protozoans of the genus Trypanosoma. Current treatment regimens against these endemic diseases have several limitations in terms of safety, efficacy, route of administration, and some of them have lost efficacy due to the emergence of resistance in their respective parasites. In this review, the most promising compounds identified by different strategies of drug development against these neglected diseases, including target-based approach, the phenotypic high-throughput screening, the drug repurposing approach, and combination therapy, are emphasized. The potent heterocyclic compounds currently undergoing pre-clinical or clinical studies have also been assessed to ascertain an effective class of organic compounds having significant therapeutic potential against these tropical diseases. The molecular hybridization of outlined motifs may result in more active compounds and circumvent the development of resistance by specific targets in the future.
Biography:
Mudasir Nabi Peerzada done his Phd in Medicinal Chemistry Research Laboratory, JMI, New Delhi. Hameldiscovered the CSA4 antitumor drug along with Professor G. R. Pettit in 1989 and he ispresently the senior investigator at National Cancer Institute, NIH, Maryland USA,where he is mentoring the group of scientists. Professor Supuran is the inventor of SLC0111 antitumor agent, discoverer of eta-carbonic anhydrases and having more than95000 citations. He is the most cited scientist in the field of cancer drug discoveryresearch in the world having more than 1700 research papers to his credit and forty yearsof research experience in this field.This research entitled as “Deciphering the key heterocyclic scaffolds in targetingmicrotubules, kinases and carbonic anhydrases for cancer drug development”is publishedinthe high impact medical journal “Pharmacology & Therapeutics”(5 year impact factor11.40). This journal is included in the Index Medicus.